Marktführer für Präzisionsmedizin Caprion-HistoGeneX rebrandet als CellCarta prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
26 gennaio 2021 MONTREAL, Jan. 26, 2021 /PRNewswire/ Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity. The new name for the Montreal-headquartered company stems from the 2019 combination of contract research organization Caprion Biosciences, which specializes in immunology and proteomics services, and HistoGeneX, a provider of histopathology and genomics services based in Antwerp. Recently, CellCarta further expanded its scientific capabilities and geographic presence through the acquisitions of Nova Scotia-based Clinical Logistics Inc. and California-based Mosaic Laboratories LLC. As a result, CellCarta is well positioned to serve the global clinical trial requirements of its pharmaceutical and bio-tech clients with state-of-the-art facilities in the United States, Canada, Europe and China. CellCarta is backed by Arsenal Capital Partners.
Press release content from PR Newswire. The AP news staff was not involved in its creation. Caprion-HistoGeneX Expands its Histological Biomarker Franchise by Joining Forces with Mosaic Laboratories January 12, 2021 GMT MONTREAL, Jan. 12, 2021 /PRNewswire/ - Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners (“Arsenal”), announced today the acquisition of Mosaic Laboratories LLC (“Mosaic”), a California-based company offering histology and immunohistochemistry services to global pharmaceutical clients. The addition of Mosaic further strengthens the North American base for Caprion-HistoGeneX’s histopathology assay development and deployment, expands the volume of pathology services and consolidates the company’s position as a world-leading service provider of histopathology biomarker analysis for global clinical trials.